Thank you for Subscribing to Life Science Review Weekly Brief
Europe is emerging as a frontier in the life sciences industry due to which a regulated investment in the domain has become crucial via increased venture capital.
FREMONT, CA: Europe holds major accountability for the number of scientific publications produced globally with a definite quality of research per the count of citations in the thesis. Similarly, the continent holds ground to maximum topped universities with comparatively an increased output and varied amounts of high-value patents annually. Yet, life sciences funding in Europe is intensely limited to utilisation when compared to the other nations' startups, and thus the region’s share of total venture capital dollars faces a decline of 21–24 per cent. Therefore, the early stage of funding experiences a severe lack despite the mature signs of growth capital.
However, the Europe tech ecosystem faces an immense variation to that of the life sciences funding as technology investing in the region is typically surging especially over a decade. That is, the continent's tech venture investments have surpassed 13 billion USD and are expected to increase in the future. Similarly, the European Public Offering managed to raise 105 billion USD and is developing as one of the thriving competitors globally. This cultural shift in Europe managed to unlock a wave of talent in various sectors with the advent of varied accelerators accordingly. This thriving success in the tech space is facilitating breakthrough innovation in the biotech sector in terms of investment.
To lead biotech innovation to a new brand horizon, Europe ought to adapt to various key factors. The region, with its global leadership in fundamental science, often promotes the scaling growth of biotech companies with its executive talent pool in pharma.
Hence, the continent serves as the headquarters for mastering pharmaceutical companies with decades and centuries of experience. Moreover, supporting budding biotech companies with potential, in their early stages facilitates a major outcome all across the continent.
One drawback that held back European biotechs in the previous decades was a lack of ambition, which has been significantly addressed in recent times. As a result, biotech companies are increasingly developed in Europe, especially in the UK. The enterprises in the United Kingdom account for nearly 60 per cent of entire Europe’s biotech venture capital, favouring a surge in investments of 5.6 billion USD and is likely to increase furthermore in the future. That is, Great Britain accounts for nearly 3,450+ companies in the domain of biotech R&D, thus accelerating Europe’s investment growth in the discipline.
Moreover, new funds are constantly launched to compete in attracting high-ranked startups to their portfolios leading to massive growth in the venture market owing to the largely driven investors. Therefore, Europe remains pivotal in the science domain, which led to the spinoff of the biotech industry while playing a crucial role in the COVID-19 pandemic that encircled the importance of innovations in life sciences for patients on a regular note. Investing in a European life-science startup at its initial stage opens to an increased value for investors with long-term strategies for progressions in the domain along with a profitable investment return.